Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaChronic myeloid leukemia: reminiscences and dreamsThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLThe emerging role of CaMKII in cancerInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsAffinity-Based Probes Based on Type II Kinase Inhibitorsc-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's DiseaseDevelopment of novel ACK1/TNK2 inhibitors using a fragment-based approachA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.A chemical and phosphoproteomic characterization of dasatinib action in lung cancerA miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsiesBosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibChemical proteomics: terra incognita for novel drug target profiling.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Chemistry-based functional proteomics for drug target deconvolution.Control of mammary tumor differentiation by SKI-606 (bosutinib).Novel targeted therapies for eosinophil-associated diseases and allergyIdentification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsPhosphoproteomics in cancerBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsAllografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.Microfluidic whole blood testing of platelet response to pharmacological agents.Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.Activation of abl family kinases in solid tumors.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureSelective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.
P2860
Q24607114-9B63B704-6C78-46CD-9463-DF6C474D713BQ26748769-ABA31EEC-625B-4745-A40F-41A9E9EAFDBEQ26866312-6140D591-C5FE-4BC7-8FEF-D7E028A6A772Q26995205-F540E42C-D6A0-4530-955E-A78B28736149Q27004027-FA0F35FF-8561-4C79-83FC-6D8A03FC24DBQ27004032-6E2EFF5A-9818-433A-9534-58915A6B1AA6Q27674665-E2F11B00-A0BC-4F76-A317-A8E82632EB55Q28070292-647E7AA4-2FE7-488C-89E9-0F140F40F23EQ28257452-625195F3-462B-4CA3-8FF6-A2C0BF01DB11Q28534337-27AE2331-4B5D-4A68-A4E3-F80BCC27FBD1Q30243925-72F7B256-29C1-4126-A7A4-1CA203CDA3C0Q30396736-E9F1F69E-987A-45AB-91A0-05EB05531B90Q33414487-1C621B09-6F21-4B93-B0EE-79B15559F829Q33434675-10A3A073-0ACE-4D17-BF68-E202E1953FDBQ33442587-8712096F-6098-4724-A9A3-BEF10EB18EE7Q33584613-6C4F8CCB-B8FC-4FC1-A59F-7E2F461CFAD5Q33742159-CAC10E3E-BD05-4A2B-B5DE-1C8C9EBD97CDQ34024820-66F00607-3851-476C-AE69-431E51B0504DQ34026441-E8F469AF-B9DE-407D-847A-3A8507FE0310Q34121339-0C64C615-A18F-4B76-A650-0A94D5845748Q34210528-AE0B638A-4D89-40F8-B313-87DCF0D1F949Q34284580-1FCC88AA-437C-460A-B57D-DBBA11D5784CQ34297594-0A6F09A5-1D03-4B27-87CF-B2E71483F929Q34342905-D46109A9-C8FB-4C64-B767-A4C91C35AA95Q34398204-77D64E5B-EE1D-4203-BC56-8F7E3B91A254Q34444620-B2DF73D1-0CFE-411E-A7DC-721145E88448Q34458274-78D86898-E203-40C0-8B00-4F718B857D54Q34539788-B2555ABF-9DAC-4A7B-8149-8EEBCC60D546Q34763374-CF8950CC-1E47-4186-954B-BBDE2D139E45Q35008618-45802F90-27F5-4DFC-8604-2EABD5272163Q35743878-E24276D7-7ED5-49E8-B8AA-C2396DFF8B88Q36169317-64FD9D40-0960-44E5-98EB-6905EF06ACF8Q36253661-E301199E-4686-4C5A-9AE4-5E79C6CB6753Q36270666-9C4290CE-6A0B-4D10-B944-C61D93777AD2Q36386366-00AE0FE6-3FB7-48B0-9240-33067A57C83FQ36394668-9B9E4086-58F2-4498-9B33-D62456761F57Q36443421-AF314F94-0AC3-4616-B8A1-E02251FD1A89Q37027759-18FBCD2A-ACED-4AB4-9970-14DE81CF8982Q37058890-0134AF76-948A-43B4-9BA3-E9F725822E77Q37069163-69C74F38-5A4A-4460-95E2-8B35EA6DE7C6
P2860
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Global target profile of the k ...... hronic myeloid leukemia cells.
@en
Global target profile of the k ...... hronic myeloid leukemia cells.
@nl
type
label
Global target profile of the k ...... hronic myeloid leukemia cells.
@en
Global target profile of the k ...... hronic myeloid leukemia cells.
@nl
prefLabel
Global target profile of the k ...... hronic myeloid leukemia cells.
@en
Global target profile of the k ...... hronic myeloid leukemia cells.
@nl
P2093
P2860
P921
P356
P1433
P1476
Global target profile of the k ...... hronic myeloid leukemia cells.
@en
P2093
C Baumgartner
K L Bennett
L L Remsing Rix
M Augustin
P2860
P2888
P304
P356
10.1038/LEU.2008.334
P577
2008-11-27T00:00:00Z
P5875
P6179
1043735889